Hinova Pharmaceuticals Inc.

The company is a global innovative pharmaceutical company focusing on cancer and metabolic diseases. With the mission of “creating good medicine and helping the world”, the company focuses on providing patients with effective, safe, and affordable drugs, and is committed to developing and producing innovative drugs that meet major clinical needs and have global benefits. The company is an innovation-driven international innovative pharmaceutical company. Based on platforms such as PROTAC technology for targeted protein degradation and deuteration technology, the company focuses on research and development of innovative drugs in therapeutic fields such as cancer and metabolic diseases with significant market potential. Main products: HC-1119, HP518, HP501, HP537. Corporate honors: 2019 China's Chemical Research and Development Strength Ranking TOP100, 2020 China's New Health Force · New Chemical Formulation Industry New Power Enterprise, 100 Key Cultivating Enterprises for the New Economy in Chengdu, etc. Top 30 innovative Chinese small molecule pharmaceutical companies in 2022; second prize of the “Rong Piao Cup” first postdoctoral innovation and entrepreneurship competition in 2023.